Oyvind Bruland
Overview
Explore the profile of Oyvind Bruland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
262
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hompland I, Boye K, Wiedswang A, Papakonstantinou A, Rosok B, Joensuu H, et al.
Acta Oncol
. 2024 May;
63:288-293.
PMID: 38712513
Introduction: Metastatic gastrointestinal stromal tumour (GIST) is considered incurable, and life-long treatment with tyrosine kinase inhibitors is recommended. We investigated whether selected patients with metastatic GIST may remain in durable...
2.
Barnes D, Dutton P, Bruland O, Gelderblom H, Faleti A, Buhnemann C, et al.
BMC Cancer
. 2022 Jun;
22(1):629.
PMID: 35672690
The phase III clinical study of adjuvant liposomal muramyl tripeptide (MTP-PE) in resected high-grade osteosarcoma (OS) documented positive results that have been translated into regulatory approval, supporting initial promise for...
3.
Konig M, Osnes T, Bruland O, Hall K, Bratland A, Meling T
Front Oncol
. 2020 Aug;
10:1402.
PMID: 32850452
Tumors originating from the craniofacial region usually present in a locally advanced stage with frequent involvement of adjacent sites and have a strong tendency for local recurrence in the absence...
4.
Thorkildsen J, Taksdal I, Bjerkehagen B, Haugland H, Johannesen T, Viset T, et al.
Acta Oncol
. 2019 Jan;
58(3):273-282.
PMID: 30632866
Background: Knowledge of chondrosarcoma (CS) of bone to date is based on institutional reports and registry publications with limits in reporting, detail and quality of data. Method: We have performed...
5.
Koksal H, Muller E, Inderberg E, Bruland O, Walchli S
Scand J Immunol
. 2018 Dec;
89(3):e12741.
PMID: 30549299
Novel therapies to treat patients with solid cancers that have developed resistance to chemotherapy represent unmet needs of considerable dimensions. In the present review, we will address the attempts to...
6.
Heinrich D, Bruland O, Guise T, Suzuki H, Sartor O
Future Oncol
. 2018 Jun;
14(24):2543-2556.
PMID: 29925281
Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies...
7.
Parker C, Finkelstein S, Michalski J, OSullivan J, Bruland O, Vogelzang N, et al.
Eur Urol
. 2016 Jun;
70(5):875-883.
PMID: 27344296
Background: The phase 3 ALSYMPCA trial enrolled metastatic castration-resistant prostate cancer patients with or without baseline opioid use. Objective: To assess the efficacy and safety of radium-223 dichloride (radium-223) versus...
8.
Varghese M, Bruland O, Wiedswang A, Lobmaier I, Rosok B, Benjamin R, et al.
Clin Sarcoma Res
. 2016 Feb;
6:2.
PMID: 26913180
Background: Abdominal leiomyosarcoma arising from the mesentery is a rare malignancy. It is an aggressive entity with an overall 5 year survival rate between 20 and 30 %. Surgical resection...
9.
Heyerdahl H, Abbas N, Sponheim K, Mollatt C, Bruland O, Dahle J
Curr Radiopharm
. 2013 Apr;
6(2):106-16.
PMID: 23551111
Unlabelled: The aim of the current study was to investigate the therapeutic effect of 227Th-radioimmunotherapy on intraperitoneally growing human bioluminescent HER2 positive ovarian cancer cells. Methods: In vitro toxicity of...
10.
Sartor O, Bruland O
Clin Genitourin Cancer
. 2011 Sep;
9(1):1-2.
PMID: 21925102
No abstract available.